Similar articles

• The importance of patent sharing in neglected disease drug discovery.

  Edlin C. Edlin C. Future Med Chem. 2011 Sep;3(11):1331-4. doi: 10.4155/fmc.11.101. Future Med Chem. 2011. PMID: 21879838 No abstract available.
• Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.

  Ioset JR, Chang S. Ioset JR, et al. Future Med Chem. 2011 Sep;3(11):1361-71. doi: 10.4155/fmc.11.102. Future Med Chem. 2011. PMID: 21879842
• New models for pharmaceutical innovation in low-income countries.

  Ardal C, Iversen JH, Myhr K. Ardal C, et al. Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658. Tidsskr Nor Laegeforen. 2011. PMID: 22016131 English, Norwegian. No abstract available.
• In silico repositioning of approved drugs for rare and neglected diseases.

  Ekins S, Williams AJ, Krasowski MD, Freundlich JS. Ekins S, et al. Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Epub 2011 Mar 1. Drug Discov Today. 2011. PMID: 21376136 Review.
• The Drug Discovery Portal: a resource to enhance drug discovery from academia.

  Clark RL, Johnston BF, Mackay SP, Breslin CJ, Robertson MN, Harvey AL. Clark RL, et al. Drug Discov Today. 2010 Aug;15(15-16):679-83. doi: 10.1016/j.drudis.2010.06.003. Epub 2010 Jun 12. Drug Discov Today. 2010. PMID: 20547242 Review.